Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Millendo Therapeutics"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Millendo Therapeutics Provides Pipeline and Business Update","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Millendo Therapeutics"},{"orgOrder":0,"company":"Organon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Organon"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Institutional Review Board","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of its Recently Initiated Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tauriga Sciences"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Inc. Receives Notification From the PCT That Its International Patent Application Has Been Published (Publication No. WO2021\/188612)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tauriga Sciences"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$945.0 million","upfrontCash":"$75.0 million","newsHeadline":"Organon to Acquire Forendo Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Organon"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences, Inc. Receives Notice of Publication from the U.S. Patent and Trademark Office","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tauriga Sciences"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$945.0 million","upfrontCash":"$75.0 million","newsHeadline":"Organon Completes Acquisition of Forendo Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Organon"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Organon

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Organon Completes Acquisition of Forendo Pharma

Details:

Through the acquisition, Organon will also acquire Forendo’s pipeline including it's lead candidate, FOR-6219, an investigational, potentially first-in-class oral 17beta-hydroxysteroid dehydrogenase type 1 inhibitor entering Phase 2 clinical development for endometriosis.

Lead Product(s): FOR-6219

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FOR-6219

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Organon

Deal Size: $945.0 million Upfront Cash: $75.0 million

Deal Type: Acquisition December 13, 2021

ASK
US

Upload
your Pipeline Activity

Organon

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Organon to Acquire Forendo Pharma

Details:

Acquisition of Forendo further demonstrates Organon's commitment to build a pipeline of impactful treatment options for women with unmet medical needs, which include Forendo’s lead investigational clinical compound, FOR-6219.

Lead Product(s): FOR-6219

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FOR-6219

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Organon

Deal Size: $945.0 million Upfront Cash: $75.0 million

Deal Type: Acquisition November 11, 2021

ASK
US

Upload
your Pipeline Activity

Tauriga Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tauriga Sciences, Inc. Receives Notice of Publication from the U.S. Patent and Trademark Office

Details:

Cannabidiol, is the second most prevalent active ingredient in cannabis (marijuana) used for anxiety, pain, a muscle disorder called dystonia, Parkinson disease, Crohn disease, and many other conditions.

Lead Product(s): Cannabidiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 01, 2021

ASK
US

Upload
your Pipeline Activity

Tauriga Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tauriga Sciences Inc. Receives Notification From the PCT That Its International Patent Application Has Been Published (Publication No. WO2021/188612)

Details:

Company’s proposed pharmaceutical, Cannabinoid based, chewing Gum product (sublingual absorption-delivery system) under development for the treatment of nausea derived from active chemotherapy treatment.

Lead Product(s): Cannabidiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 06, 2021

ASK
US

Upload
your Pipeline Activity

Tauriga Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of its Recently Initiated Clinical Trial

Details:

The Company’s proposed Cannabidiol delivery system (via: sublingual absorption / oral mucosa), utilizes its proprietary Cannabidiol infused chewing gum platform.

Lead Product(s): Cannabidiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Institutional Review Board

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding September 13, 2021

ASK
US

Upload
your Pipeline Activity

Organon

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

Details:

The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo’s therapeutic concept.

Lead Product(s): FOR-6219

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FOR-6219

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2021

ASK
US

Upload
your Pipeline Activity

Millendo Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Millendo Therapeutics Provides Pipeline and Business Update

Details:

While MLE-301 was generally well-tolerated, the data do not support moving forward with its development in the target population of peri- and post-menopausal women, especially with the evolving dynamics of a highly competitive NK3R antagonist market.

Lead Product(s): MLE-301

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 05, 2021

ASK
US

Upload
your Pipeline Activity

Millendo Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist

Details:

The single ascending dose portion of the study will be conducted in healthy male volunteers, to determine the pharmacokinetics of MLE-301 and its pharmacodynamic profile as measured by reductions of biomarkers (luteinizing hormone, testosterone).

Lead Product(s): MLE-301

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 24, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY